Last updated: August 4, 2026
Palladone was a once-daily extended-release hydromorphone capsule launched by Purdue Pharma in the United States in early 2005 and withdrawn voluntarily within months after FDA identified a serious alcohol-related dose-dumping risk. Its commercial trajectory was therefore defined by rapid market entry, limited revenue capture, immediate discontinuation, and the loss of a potential premium opioid franchise.
The product generated no durable commercial platform. Palladone’s withdrawal removed Purdue’s opportunity to compete in the long-acting opioid market alongside OxyContin and eliminated the near-term value of its extended-release hydromorphone formulation.
What was Palladone and who marketed it?
Palladone was an extended-release oral formulation of hydromorphone hydrochloride, a potent opioid analgesic. Purdue Pharma marketed the product in the United States under NDA 021217. The dosage form was a once-daily capsule intended for patients requiring continuous opioid therapy for persistent pain.
| Attribute |
Palladone |
| Active ingredient |
Hydromorphone hydrochloride |
| Formulation |
Extended-release capsule |
| Route |
Oral |
| Brand owner and marketer |
Purdue Pharma |
| FDA application |
NDA 021217 |
| Therapeutic category |
Long-acting opioid analgesic |
| U.S. approval |
2004 |
| Commercial launch |
Early 2005 |
| U.S. withdrawal |
July 2005 |
| Current U.S. status |
Discontinued and no longer marketed |
Palladone was positioned as a controlled-release alternative to immediate-release hydromorphone and as a potential competitor to OxyContin, Purdue’s much larger extended-release oxycodone product.
When did Palladone lose exclusivity and market access?
Palladone lost commercial exclusivity through withdrawal rather than through ordinary patent expiry or generic substitution. FDA and Purdue announced the voluntary withdrawal in July 2005 after testing showed that alcohol could cause rapid release of hydromorphone from the capsule, increasing the risk of opioid toxicity and fatal respiratory depression.[1]
The key timeline was:
| Date |
Event |
Commercial effect |
| 2004 |
FDA approved Palladone |
Established regulatory entry |
| Early 2005 |
U.S. launch |
Began commercial sales |
| July 2005 |
FDA and Purdue announced withdrawal |
Stopped new commercial sales |
| August 2005 |
Product removal from distribution completed |
Ended ordinary market access |
| Post-2005 |
No sustained relaunch |
Eliminated long-term brand revenue |
The product did not proceed through a normal loss-of-exclusivity cycle. A generic manufacturer would have had limited commercial incentive to launch against a product that had already been removed from the market.
Why was Palladone withdrawn?
Palladone was withdrawn because alcohol could compromise the extended-release mechanism. FDA testing showed that co-administration with alcohol could produce rapid release of hydromorphone, a phenomenon commonly called dose dumping.[1]
The risk was commercially material because:
- Hydromorphone is substantially more potent than morphine on a milligram basis.
- The product was designed for prolonged release over approximately 24 hours.
- Alcohol exposure is common in the general population and could not be reliably excluded.
- A failure of the release mechanism could create a large acute opioid exposure.
- Risk mitigation through labeling was considered inadequate for the marketed formulation.
FDA described the issue as a product-quality and formulation-safety problem rather than a failure of hydromorphone as an analgesic. The withdrawal applied to Palladone’s formulation and commercial presentation.
How large was the Palladone market opportunity?
Palladone entered a large and growing U.S. market for long-acting opioid analgesics. Purdue had already established OxyContin as a major branded opioid, and long-acting opioid prescribing expanded during the period before the opioid crisis produced broad regulatory and commercial contraction.
Palladone’s opportunity was based on four commercial factors:
- Hydromorphone had a recognized role in severe pain management.
- Once-daily dosing offered a convenience advantage.
- Extended-release products generally supported higher unit economics than immediate-release products.
- Purdue possessed an established pain-management sales infrastructure.
The product also had substantial commercial constraints. Hydromorphone was a narrower market than oxycodone, and extended-release opioids faced competition from OxyContin, MS Contin, fentanyl patches and other controlled-release products. Palladone’s short market exposure prevented Purdue from building meaningful prescriber persistence or payer coverage.
What was Palladone’s financial trajectory?
Public filings do not provide a reliable, separately reported Palladone revenue series. Purdue was privately held during the relevant period, and its public financial disclosures did not establish a product-level sales history sufficient to calculate launch revenue, gross margin or cumulative losses for Palladone.
The financially supportable trajectory is therefore:
| Financial phase |
Likely business condition |
Evidence-based assessment |
| Pre-launch |
Development and regulatory investment |
Costs included formulation development, clinical work, manufacturing readiness and launch preparation |
| Early 2005 |
Initial revenue generation |
Sales began, but the product had only a short selling period |
| July-August 2005 |
Immediate revenue collapse |
Withdrawal ended ordinary sales |
| Post-withdrawal |
No recurring product revenue |
Remaining value was limited to inventory, regulatory rights and intellectual property |
| Long term |
Opportunity loss |
Purdue forfeited a potential extended-release hydromorphone franchise |
Palladone’s direct revenue was likely small relative to OxyContin because the product was sold for only several months. Any estimate stated as a precise dollar amount would not be supported by the available public record.
The larger financial effect was opportunity cost. Purdue had invested in a product that could have expanded its opioid portfolio, used its existing sales force and generated recurring prescription revenue. Withdrawal converted those investments into largely stranded costs.
How did Palladone compare with OxyContin?
Palladone and OxyContin occupied the same broad market category but differed in active ingredient, market scale and commercial durability.
| Factor |
Palladone |
OxyContin |
| Active ingredient |
Hydromorphone |
Oxycodone |
| Release profile |
Extended release |
Extended release |
| Intended dosing |
Once daily |
Generally every 12 hours in original labeling |
| Purdue market role |
New product launch |
Core opioid franchise |
| Commercial duration |
Several months |
Long-term U.S. commercialization |
| Market scale |
Narrower hydromorphone segment |
Large branded opioid segment |
| Key formulation event |
Alcohol-related dose dumping and withdrawal |
Later reformulation and abuse-deterrence strategy |
| Revenue contribution |
Limited and short-lived |
Material historical contributor to Purdue |
Palladone did not materially diversify Purdue’s dependence on OxyContin. Its withdrawal left Purdue with a concentrated exposure to oxycodone and other opioid products.
What patents protected Palladone?
Palladone’s protection depended on a combination of formulation technology, controlled-release design, regulatory exclusivity and any listed patents associated with NDA 021217. The commercial value of those rights fell sharply after withdrawal.
The relevant IP categories were:
Extended-release formulation patents
These rights could cover:
- Hydromorphone embedded in a controlled-release matrix or delivery system.
- Release-rate characteristics.
- Excipients and manufacturing parameters.
- Protection against rapid release under ordinary administration conditions.
- Dosage forms supporting once-daily administration.
Method-of-use patents
Potential method-of-use protection could cover:
- Administration of extended-release hydromorphone for persistent pain.
- Once-daily dosing.
- Use in opioid-tolerant patients.
- Dose titration or maintenance treatment.
Method-of-use claims would have had limited practical value after the product was withdrawn because they could not solve the central formulation defect.
Orange Book status
FDA’s Orange Book records identify discontinued drug products and associated regulatory information, but Orange Book listing does not guarantee current commercial enforceability or market value. Palladone’s listing became commercially secondary after the product was removed from distribution.[2]
There was no durable generic-entry contest comparable to the later challenges against major opioid brands. The product’s withdrawal prevented the normal patent-expiry cycle from becoming the main driver of competition.
Were there Paragraph IV challenges to Palladone?
No major, commercially consequential Paragraph IV challenge is associated with Palladone’s short U.S. market life in the public regulatory record.
A Paragraph IV filing would have challenged the validity, enforceability or non-infringement of an Orange Book-listed patent in an abbreviated new drug application. Such a challenge typically matters when:
- The reference product has sustained prescription demand.
- The generic applicant can obtain a 180-day exclusivity position.
- Litigation can delay approval or launch.
- The expected market supports the cost of patent litigation.
Those conditions weakened rapidly after the July 2005 withdrawal. The expected return from a generic Palladone launch fell because the brand was no longer commercially active and prescriber demand had not matured.
Which companies challenged or replaced Palladone?
No company established a major generic Palladone franchise after the withdrawal. The commercial replacement set consisted of other opioid products rather than a direct generic takeover.
Competitive products included:
- OxyContin, marketed by Purdue.
- Immediate-release hydromorphone products, including generic Dilaudid equivalents.
- MS Contin and other extended-release morphine products.
- Transdermal fentanyl products.
- Later extended-release hydromorphone products, including Exalgo.
Exalgo, approved by FDA in 2010, became the more relevant branded extended-release hydromorphone comparator. It was developed and marketed by Covidien and later associated with other commercial rights holders. Exalgo’s later approval showed that extended-release hydromorphone retained therapeutic and commercial interest, but it did not restore Palladone’s market position.[3]
What was the FDA regulatory status of Palladone?
Palladone is not an active U.S. commercial product. FDA records classify it as discontinued, and Purdue did not maintain ordinary marketing after the 2005 withdrawal.
The regulatory sequence was significant:
- FDA approved the product in 2004.
- Post-approval testing identified alcohol-related rapid release.
- FDA issued a public health communication.
- Purdue voluntarily withdrew the product.
- The formulation was not broadly relaunched in its original form.
The withdrawal also affected the regulatory economics of future development. Any relaunch would have required a new formulation strategy, additional safety evidence and renewed regulatory investment. A company could not simply resume sales of the withdrawn presentation without resolving the dose-dumping mechanism and satisfying FDA requirements.
What litigation affected Palladone?
The principal legal and regulatory event was the FDA-coordinated product withdrawal. Palladone did not develop a litigation profile comparable to OxyContin, which later became central to extensive opioid-related civil, criminal and bankruptcy proceedings.
Palladone nevertheless carried litigation exposure in three areas:
- Product liability claims alleging injury from opioid toxicity.
- Commercial disputes concerning inventory, distribution and contractual obligations.
- Broader Purdue opioid litigation affecting corporate value and product governance.
The public record does not support treating Palladone as a major independent driver of Purdue’s later opioid litigation. Its short sales period limited the volume of exposure relative to longer-marketed opioid products.
How strong was Palladone’s patent estate?
Palladone’s patent estate had technical relevance but weak realized economic value.
| Strength factor |
Assessment |
| Active-ingredient protection |
Weak, because hydromorphone was an established molecule |
| Formulation protection |
Potentially meaningful, but undermined by alcohol dose dumping |
| Method-of-use protection |
Limited practical value after withdrawal |
| Regulatory exclusivity |
Short commercial utility because the product was withdrawn |
| Generic barrier |
Functionally strong after withdrawal, but because the market disappeared |
| Manufacturing know-how |
Potentially valuable for a corrected formulation, not for the withdrawn product |
| Licensing value |
Low without a viable reformulation and regulatory pathway |
The key distinction is between legal exclusivity and economic exclusivity. Even a technically defensible formulation patent would not preserve value if the formulation could not be marketed safely.
Did Purdue license Palladone or monetize the assets?
No major Palladone-specific licensing transaction is broadly documented as a material commercial event. The product was primarily a Purdue-controlled development and marketing project.
After withdrawal, potential monetization routes would have included:
- Licensing a redesigned hydromorphone extended-release formulation.
- Selling formulation know-how.
- Transferring regulatory rights.
- Using the technology in a new product with improved alcohol resistance.
No sustained transaction or relaunch established meaningful post-withdrawal value for the original Palladone product.
What generic launch scenarios existed for Palladone?
The realistic generic scenarios were limited.
Scenario 1: No generic launch
This was the commercial outcome. Withdrawal eliminated the reference product’s active market and reduced the incentive for an ANDA applicant.
Scenario 2: Generic entry after technical substitution
A generic applicant could have sought approval for an extended-release hydromorphone product with a different formulation. That product would have faced a regulatory and clinical burden if its performance differed materially from the withdrawn reference product.
Scenario 3: Reformulated branded replacement
A redesigned product with alcohol-resistant release characteristics could have entered under a new or supplemental regulatory strategy. Exalgo later occupied this broader therapeutic space, reducing the need to revive Palladone.
What manufacturing and IP barriers affected Palladone?
The central barrier was not hydromorphone supply. Hydromorphone was an established active pharmaceutical ingredient. The barrier was manufacturing a controlled-release system that remained reliable in the presence of alcohol.
Important technical requirements included:
- Consistent drug release over the intended dosing interval.
- Resistance to alcohol-induced disruption.
- Tight control of particle size and excipient composition.
- Reproducible dissolution performance.
- Commercial-scale manufacturing without unacceptable batch variability.
- Stability across storage conditions.
A successful successor would require formulation redesign, dissolution testing, alcohol-interaction studies and FDA review. Those requirements raised development cost and extended time to market.
What was Palladone’s geographic coverage?
Palladone’s commercially relevant market was the United States. The public record does not establish a significant international commercial franchise comparable to Purdue’s U.S. opioid business.
The U.S. withdrawal had a disproportionate effect because:
- The U.S. was the principal commercial market for high-dose long-acting opioid analgesics.
- Purdue’s sales infrastructure was U.S.-centered.
- The product’s regulatory issue directly affected the U.S. formulation approved by FDA.
- International expansion would have required separate regulatory approvals and commercial partnerships.
What is Palladone’s current commercial value?
The original product has negligible current commercial value as a marketed drug. Its residual value is limited to historical know-how, formulation concepts and any surviving IP that could support a redesigned product.
Palladone has continuing analytical importance because it demonstrates how a formulation defect can destroy the economics of a high-value controlled-release drug before generic competition begins. The product’s failure was caused by the interaction between formulation design, real-world patient behavior and the risk tolerance of opioid regulation.
Key Takeaways
- Palladone was Purdue Pharma’s once-daily extended-release hydromorphone product.
- FDA approved it in 2004 and the product launched in early 2005.
- FDA and Purdue withdrew it in July 2005 after alcohol-related dose dumping raised overdose concerns.
- Public filings do not provide a reliable product-level Palladone revenue figure.
- Its direct revenue was limited by the short commercial period.
- The larger financial loss was the destruction of a potential long-acting opioid franchise.
- No major Paragraph IV challenge or generic Palladone market developed.
- Formulation patents and manufacturing know-how had limited value after withdrawal.
- Exalgo later re-established extended-release hydromorphone as a viable regulatory and commercial category.
- Palladone is not an active U.S. marketed product.
FAQs About Palladone Market Dynamics
Was Palladone the same drug as Dilaudid?
No. Both contained hydromorphone, but Dilaudid was primarily an immediate-release hydromorphone product, while Palladone was an extended-release, once-daily formulation.
Did Palladone make substantial revenue for Purdue?
There is no reliable public product-level revenue disclosure. Because Palladone was marketed for only several months, its cumulative revenue was limited compared with Purdue’s long-running OxyContin business.
Can a generic company still launch Palladone?
A generic company could not ordinarily launch the withdrawn brand presentation as a normal market substitute. Any successor would require FDA approval and would need to address the formulation’s alcohol-related release problem.
Was Palladone withdrawn because hydromorphone was ineffective?
No. The withdrawal concerned the extended-release formulation’s alcohol-related dose-dumping risk, not the underlying analgesic activity of hydromorphone.
Why did Exalgo succeed where Palladone failed?
Exalgo entered with a later formulation and regulatory strategy designed for extended-release hydromorphone. Its market position did not revive Palladone, but it demonstrated that the therapeutic category could be commercially pursued with a different product design.
References
- U.S. Food and Drug Administration. (2005, July 13). Palladone: FDA public health advisory. FDA.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2010). FDA approves extended-release hydromorphone hydrochloride tablets for management of pain. FDA.
